Illumina, Inc. Files 8-K Report

TL;DR

Illumina filed an 8-K on 6/22/25 for a material agreement.

AI Summary

On June 22, 2025, Illumina, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes other events and financial statements and exhibits. The company is based in San Diego, California.

Why It Matters

This 8-K filing indicates a significant event or agreement for Illumina, Inc., which could impact its business operations and financial standing.

Risk Assessment

Risk Level: low — The filing is a standard disclosure of a material definitive agreement and does not inherently suggest immediate financial risk.

Key Players & Entities

• Illumina, Inc. (company) — Registrant
• June 22, 2025 (date) — Date of earliest event reported
• San Diego, CA (location) — Principal executive offices

FAQ

From the Filing

0001193125-25-144290.txt : 20250623 0001193125-25-144290.hdr.sgml : 20250623 20250623092449 ACCESSION NUMBER: 0001193125-25-144290 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20250622 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250623 DATE AS OF CHANGE: 20250623 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ILLUMINA, INC. CENTRAL INDEX KEY: 0001110803 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 330804655 STATE OF INCORPORATION: DE FISCAL YEAR END: 1228 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35406 FILM NUMBER: 251063164 BUSINESS ADDRESS: STREET 1: 5200 ILLUMINA WAY CITY: SAN DIEGO STATE: CA ZIP: 92122 BUSINESS PHONE: 8582024500 MAIL ADDRESS: STREET 1: 5200 ILLUMINA WAY CITY: SAN DIEGO STATE: CA ZIP: 92122 FORMER COMPANY: FORMER CONFORMED NAME: ILLUMINA INC DATE OF NAME CHANGE: 20000331 8-K 1 d66921d8k.htm 8-K 8-K false 0001110803 0001110803 2025-06-22 2025-06-22     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Form 8-K     Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2025         Illumina, Inc. (Exact name of registrant as specified in its charter)     001-35406 (Commission File Number)   Delaware   33-0804655 (State or other jurisdiction of incorporation)   (I.R.S. Employer Identification No.) 5200 Illumina Way , San Diego , CA 92122 (Address of principal executive offices) (Zip code) (858) 202-4500 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.01 par value   ILMN   The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company   ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13a of the Exchange Act. ☐       Item 1.01 Entry into a Material Definitive Agreement. On June 22, 2025, Illumina, Inc. (the “Company”) and Standard BioTools Inc. (“Standard BioTools”), a Delaware corporation, entered into a Stock Purchase Agreement (the “Purchase Agreement”). Pursuant to the Purchase Agreement, the Company will acquire (the “Acquisition”) from Standard BioTools (i) all of the issued and outstanding shares in the capital stock of SomaLogic, Inc. (“SomaLogic”), a Delaware corporation, (ii) all of the limited liability company inter